TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged ≥ 18 years at time of consent.~* Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.~* Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) PsA at time of screening.~* Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)~* May not have axial involvement alone~* Concurrent Treatment allowed with methotrexate, leflunomide, or sulfasalazine~* Have ≥ 3 swollen AND ≥ 3 tender joints.~* Males \& Females must use contraception~* Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose oral corticosteroids allowed.~Exclusion Criteria:~* Pregnant or breast feeding.~* History of allergy to any component of the investigational product.~* Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.~* Therapeutic failure on \> 3 agents for PsA or \> 1 biologic tumor necrosis factor (TNF) blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 20mg (Type: EXPERIMENTAL): 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
- Apremilast 30mg (Type: EXPERIMENTAL): 30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
- Placebo + 20 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
- Placebo + 30 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients histologically diagnosed as metastatic renal cell cancer with a component of clear cell cancer.~* Patients who are refractory to cytokine therapy as 1st line.~* Patients who experienced nephrectomy.~* Patients with at least 1 target lesion, as defined by RECIST.~* Patients with no uncontrolled hypertension.~Exclusion Criteria:~* Gastrointestinal abnormalities~* Current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2/3A4 inducers.~* Active seizure disorder or evidence of brain metastases.~* Patients with hemoptysis.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AG-013736 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~eGFR 15-59 ml/m2~Exclusion Criteria:~Current vitamin D treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol 2 microgram/d (Type: ACTIVE_COMPARATOR): None
- Paricalcitol 1 microgram/d (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibuprofen Sodium Tension Headache Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females at least 18 years to 65 years of age~* A diagnosis of an episodic tension-type headache, as defined by the International Headache Society~Exclusion Criteria:~* Pregnancy or breast-feeding~* Alcohol or substance abuse~* Any serious medical or psychiatric disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: ACTIVE_COMPARATOR): None
- Treatment C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Modified Finnish Type 2 Diabetes Risk Assessment Tool (FINDRISC) score ≥ 4~* Capillary fasting blood glucose (FBG) \< 7.0 mmol/L~* Malaysian~* Live, work or study in Kuala Nerus, Terengganu~* Both gender~* Age 18 to 59 years old~* Non-smoker~* Those taking supplement agree to undergo washout period of one week~Exclusion Criteria:~* Had clinical history of type 2 diabetes mellitus (T2DM)~* Capillary FBG ≥ 7.0 mmol/L~* Take oral antidiabetic agents~* Participate in other weight management programme or interventional research~* On a prescribed medical diet~* GI illnesses or conditions~* Allergy or sensitivity to study products~* Pregnant, currently breastfeeding, or planning to become pregnant~* On dietary restrictions~* Smoker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Formulation 3 (Type: ACTIVE_COMPARATOR): Formulated MMT peel powder (provide 5 g dietary fiber per day)
- Control (Type: PLACEBO_COMPARATOR): Glucose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Central Venous Oxygen Saturation Assisted Intraoperative Hemodynamic Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing the following elective major abdominal surgery: oesophagectomy, total gastrectomy, radical cystectomy, aorta-bifemoral bypass or elective operation of abdominal aortic aneurysm.~* after surgery patients were admitted to our intensive care unit.~Exclusion Criteria:~* patients younger than 18 years~* chronic organ insufficiency: Acute Physiology and Chronic Health Evaluation (APACHE) II scoring system: New York Heart Association Class IV, chronic hypoxia or hypercapnia, chronic renal failure requiring renal replacement therapy, biopsy proven cirrhosis or portal hypertension and immunodeficiency.~* preoperative anaemia (haemoglobin\<100g/L)~* coagulation abnormality~* and patients with chronic use of corticosteroids and non-steroid anti-inflammatory drugs~* patients requiring an operation due to malignant disease where the tumour then proved to be inoperable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
- CeVOX (Type: EXPERIMENTAL): In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline for Primary Biliary Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ages 18 to 76 years.~* Established diagnosis of PBC based on at least three of the following criteria:~  * Detectable anti-mitochondrial antibodies (AMA)~ * Cholestatic biochemical pattern~ * Liver biopsy compatible with PBC~ * Appropriate exclusion of other liver diseases.~* Therapy with UDCA at adequate dose (13-15mg/kg/d) for at least six months and evidence of suboptimal response defined by alkaline phosphatase levels that did not normalize and remain elevated by at least 1.5 times the upper limit of normal.~* No history or present hepatic decompensation (e.g. variceal hemorrhage, encephalopathy, or poorly controlled ascites).~Exclusion Criteria:~* Findings highly suggestive of liver disease of other etiology.~* A score \>=10 points on the Revised Scoring System for autoimmune hepatitis (AIH), supporting a diagnosis of PBC/AIH overlap.~* Patients on steroids (systemic), immunosuppressants, or immunomodulatory agents within the previous 6 months.~* Patients with clinical or laboratory evidence suggestive of decompensated cirrhosis.~* Hypersensitivity to PTX or the methylxanthines (caffeine, theophylline, theobromine).~* History of cerebral or retinal hemorrhage.~* Other medical comorbidities (such as cardiac, renal, cancer) that would interfere with completion of the study.~* Patients taking Theophylline or Coumadin because of potential drug-drug interactions with PTX. In addition, patients taking low molecular weight heparin preparations.~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline 400 mg TID (Type: EXPERIMENTAL): This study is an open label pilot with only one arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Anesthetic Use In Pessary Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women in the Loyola Urogynecology clinic who use a pessary for management of pelvic organ prolapse (POP) or urinary incontinence (UI)~* Read and speak the English language~Exclusion Criteria:~* Non-English speaking~* Allergy or contraindication to topical anesthetic~* Participation/randomization in the study at a previous visit~* Currently pregnant or lactating or planning a pregnancy within the next 6 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lidocaine-prilocaine (Type: EXPERIMENTAL): 4 mL of lidocaine-prilocaine cream
- Placebo (Type: PLACEBO_COMPARATOR): 4 mL of placebo cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of Schizophrenia or Schizoaffective Disorder Current Cigarette Smoker or History of Chronic Cigarette smoking Age 18-65 Currently taking antipsychotic medication~Exclusion Criteria:~prior history of hospitalization for acute myocardial infarction or stroke, or persistent angina pectoris with current symptoms Patients who have previously tried varenicline and have stopped taking it because of side-effects of severe nausea or vomiting suicide attempt in the last year and or have had prominent or serious suicidal thoughts in the past year Women who are pregnant, nursing, or unable to use reliable contraception significant renal impairment(Creatinine ≥ 1.5) baseline Hamilton Depression Scores is \>20

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Varenciline 1-2 mg/day
- Matched Placebo (Type: PLACEBO_COMPARATOR): placebo for varenicline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has a historical diagnosis of Type 2 Diabetes Mellitus.~* Has a body mass index between acceptable range.~* Is experiencing inadequate glycemic control.~* Body weight keeps constant.~* Females of childbearing potential and males who are sexually active agree to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.~Exclusion Criteria:~* Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.~* Has a systolic blood pressure beyond the acceptable range at Screening visit.~* Has New York Heart Association Class III or IV heart failure regardless of therapy.~* Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.~* Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
- Alogliptin Monotherapy (Type: EXPERIMENTAL): Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
- Metformin (Type: OTHER): Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
- Metformin + Alogliptin Add-on Therapy (Type: EXPERIMENTAL): Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
- Pioglitazone (Type: OTHER): Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
- Pioglitazone + Alogliptin Add-on Therapy (Type: EXPERIMENTAL): Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Histologically confirmed diagnosis of prostate cancer.~2. Documented evidence of metastatic castration resistant prostate cancer (mCRPC).~3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .~4. Ongoing therapy with LHRH analog or bilateral orchiectomy.~5. Radiographic progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).~6. Qualifying HRR mutation in tumor tissue.~Exclusion criteria~1. Any previous treatment with PARP inhibitor, including olaparib.~2. Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose \> 5 years prior to randomization.~3. Other malignancy (including MDS and MGUS) within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumors curatively treated with no evidence of disease for ≥5 years.~4. Subjects with known brain metastases.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Olaparib (Type: EXPERIMENTAL): Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
- Enzalutamide OR abiraterone acetate (Type: ACTIVE_COMPARATOR): Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unilateral or bilateral intermittent leg claudication which was stable for the last 6 months.~* Patients with ABPI \< 0.9 at rest at least in one leg.~* BP ≤ 160/90 and a stable medication regimen for the last 6 months.~* Able to give informed consent~* Able to comply with study protocol~Exclusion Criteria:~* Documented bilateral renal artery stenosis~* Unlikely to be compliant with medication or follow up as determined by the recruiting institution.~* Pregnancy~* Patients with critical limb ischemia (This includes patients with ischaemic rest pain and ulceration \> 2 weeks and/or a resting ankle pressure \< 50mmHg- Grades II and III according to Rutherford et al 1997.\[56\].~* Patients who had a recent (less than 3 months) angioplasty or bypass surgery~* Patients who are unable to perform a treadmill test due to a limiting heart, respiratory or arthritic disease~* History of angioneurotic oedema~* Currently taking ACE inhibitor or Angiotensin receptor blocker~* Contraindication to ACE inhibitor~* History of ACE inhibitor intolerance~* A creatinine rise of \> 30% from baseline and/or Potassium \> 5.9 mmol/l~* Unwillingness to participate.~* Level 1 evidence for ACE inhibitor treatment, including:~* Documented heart failure, left ventricular dysfunction or ejection fraction \<35% on previous echocardiography~  * Uncontrolled hypertension, BP \> 160mmHg systolic or 100mmHg diastolic on 3 separate readings measured after 10 minutes rest on 2 separate occasions~ * Recent (\< 3months) myocardial infarction or stroke~ * Chronic renal impairment (serum creatinine \> 250 micromol/l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ramipril (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Specialized Treatment Early in Psychosis (STEP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 16-45~2. Meets DSM-IV schizophrenia spectrum psychosis or affective psychosis according to the SCID~3. ≤8 weeks of received antipsychotic treatment lifetime at time of referral~4. Willing to be treated in New Haven~Exclusion Criteria:~1. Psychosis believed due to substance use (based on the SCID)~2. Unable or unwilling to give informed consent~3. MR as indicated by receipt of services from Dept of Mental Retardation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Treatment as usual (Type: ACTIVE_COMPARATOR): Referral to community providers.
- STEP Care (Type: EXPERIMENTAL): Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete